These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28689844)

  • 1. The Many "Buckets" of Severe Asthma: Moving Toward Personalized Management.
    Moore WC; Castro M
    J Allergy Clin Immunol Pract; 2017; 5(4):936-937. PubMed ID: 28689844
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biological engineering for new asthma therapy].
    Van Hage M; Grönlund H; Gafvelin G
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1942-5. PubMed ID: 18681377
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenotypes/endotypes-driven treatment in asthma.
    Braido F; Tiotiu A; Kowal K; Mihaicuta S; Novakova P; Oguzulgen IK
    Curr Opin Allergy Clin Immunol; 2018 Jun; 18(3):184-189. PubMed ID: 29601354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.
    Massanari M; Nelson H; Casale T; Busse W; Kianifard F; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2010 Feb; 125(2):383-9. PubMed ID: 20159249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in pediatric asthma in 2014: Moving toward a population health perspective.
    Szefler SJ
    J Allergy Clin Immunol; 2015 Mar; 135(3):644-52. PubMed ID: 25649079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunomodulation therapy for allergic asthma. What is already possible, what is to come?].
    Taube C; Buhl R
    Dtsch Med Wochenschr; 2008 Apr; 133(14):727-32. PubMed ID: 18363195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy.
    Rosenberg JL
    J Allergy Clin Immunol; 2011 Feb; 127(2):548; author reply 548-9. PubMed ID: 21281877
    [No Abstract]   [Full Text] [Related]  

  • 8. Allergy, Allergic Inflammation and Asthma--Keystone Symposium. Pharmacological targets in allergic inflammation and asthma.
    Kierstein S
    IDrugs; 2006 Jun; 9(6):405-8. PubMed ID: 16752308
    [No Abstract]   [Full Text] [Related]  

  • 9. Asthma: personalized and precision medicine.
    Canonica GW; Ferrando M; Baiardini I; Puggioni F; Racca F; Passalacqua G; Heffler E
    Curr Opin Allergy Clin Immunol; 2018 Feb; 18(1):51-58. PubMed ID: 29189350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving towards precision care for childhood asthma.
    Mokhallati N; Guilbert TW
    Curr Opin Pediatr; 2016 Jun; 28(3):331-8. PubMed ID: 27093356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?
    Brightling CE
    Lancet Respir Med; 2017 Feb; 5(2):92-95. PubMed ID: 28145230
    [No Abstract]   [Full Text] [Related]  

  • 12. American Academy of Allergy, Asthma & Immunology--2008 Annual Meeting.
    Bielory L
    IDrugs; 2008 May; 11(5):309-11. PubMed ID: 18465665
    [No Abstract]   [Full Text] [Related]  

  • 13. [A new boost for 100-year old therapy].
    Hedlin G
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1931. PubMed ID: 18681373
    [No Abstract]   [Full Text] [Related]  

  • 14. Update in Pediatric Asthma: Selected Issues.
    Azmeh R; Greydanus DE; Agana MG; Dickson CA; Patel DR; Ischander MM; Lloyd RD
    Dis Mon; 2020 Apr; 66(4):100886. PubMed ID: 31570159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Montelukast might improve compliance with subcutaneous immunotherapy treatments in patients with allergic asthma.
    Vaughn MP
    J Allergy Clin Immunol; 2011 Jan; 127(1):286; author reply 286-7. PubMed ID: 20850867
    [No Abstract]   [Full Text] [Related]  

  • 16. Current asthma management.
    Higgins BG
    Practitioner; 1999 May; 243(1598):376-80, 384. PubMed ID: 10534887
    [No Abstract]   [Full Text] [Related]  

  • 17. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
    Louis R; Demarche S; Van Hees T; Schleich F
    Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory and biologic therapies for severe refractory asthma.
    Polosa R; Morjaria J
    Respir Med; 2008 Nov; 102(11):1499-510. PubMed ID: 19012848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel treatments of asthma and allergic diseases.
    Chini L; Monteferrario E; Graziani S; Moschese V
    Paediatr Respir Rev; 2014 Dec; 15(4):355-62. PubMed ID: 24287269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asthma from immune pathogenesis to precision medicine.
    Khalaf K; Paoletti G; Puggioni F; Racca F; De Luca F; Giorgis V; Canonica GW; Heffler E
    Semin Immunol; 2019 Dec; 46():101294. PubMed ID: 31387788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.